Press Releases

Date Title and Summary Additional Formats
Toggle Summary SCYNEXIS Announces Appointment of Industry Veteran Marion McCourt to its Board of Directors
— Former Chief Operating Officer of Medivation adds broad experience in commercial, strategy, operations and business development — —  SCYNEXIS to ramp up commercial preparatory and territorial licensing activities for its lead product, SCY-078 — JERSEY CITY, N.J., Jan.
View HTML
Toggle Summary SCYNEXIS Achieves New Development Milestones Reinforcing the Versatility of SCY-078 in Treating Serious Fungal Infections
— Regimen of intravenous (IV) formulation of SCY-078 successfully identified and characterized to support subsequent studies — — Long-term toxicology studies completed, confirming favorable safety profile of oral SCY-078 — JERSEY CITY, N.J., Dec.
View HTML
Toggle Summary SCYNEXIS, Inc. to Participate in the Guggenheim Securities 4th Annual Boston Healthcare Conference
JERSEY CITY, N.J., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX), a pharmaceutical company developing novel anti-infectives to address unmet therapeutic needs, today announced that the Company will participate in the Guggenheim Securities 4 th Annual Boston
View HTML
Toggle Summary SCYNEXIS, Inc. Reports Third Quarter 2016 Financial Results and Provides Company Update
-- Positive Results From Multiple Studies Provide Clear Evidence of Clinical Antifungal  Activity and Favorable Safety Profile of  SCY-078 -- -- Company is Well Positioned and Capitalized to Accelerate and Expand Clinical Development of SCY-078 in Multiple Indications -- JERSEY CITY,
View HTML
Toggle Summary SCYNEXIS Completes Two Additional Clinical Studies Further Supporting the Favorable Safety Profile of SCY-078
SCY-078 demonstrates a low potential for certain drug-drug interactions — a relevant differentiator versus the azoles, the leading antifungal class — providing an opportunity for favorable labeling Significant step forward to further de-risk the ongoing development program of SCY-078
View HTML
Toggle Summary SCYNEXIS Announces Complete Results from Two Phase 2 Studies of Oral SCY-078 in Patients with Candida spp. Infections and Closing of a $15 Million Term Loan
Study Results Confirm Overall Antifungal Activity of Oral SCY-078 in Patients with Candida Infections Well-Tolerated and Active Oral Dose of SCY-078 Identified for Invasive Candidiasis Patients Evidence of Efficacy and Lower Relapse Rates versus Standard of Care in VVC Patients Strong Cash Position
View HTML
Toggle Summary SCYNEXIS, Inc. to Present at the Ladenburg Thalmann Healthcare Conference
JERSEY CITY, N.J., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference at the Sofitel New York Hotel on Tuesday, September 27, 2016 at 3:00 p.m. ET.
View HTML
Toggle Summary SCYNEXIS, Inc. to Present at Upcoming Investor Conferences
JERSEY CITY, N.J., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the following upcoming investor conferences: The Baird Global Healthcare Conference at the New York Palace Hotel on Wednesday, September 7,
View HTML
Toggle Summary SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections
First non-azole, orally and IV bioavailable antifungal agent with orphan drug designation for both invasive Aspergillus infections and invasive Candida infections
View HTML
Toggle Summary SCYNEXIS, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Update
  Positive Results from Two Phase 2 Studies Confirm Antifungal Clinical Activity of SCY-078   Company is Well Positioned and Capitalized to Advance its Clinical Programs Forward As Planned   JERSEY CITY, N.J., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc .
View HTML